Real-world use of molecular classification for endometrial cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational project collects questionnaire and clinical data from Italian hospitals that treat and surgically manage endometrial cancer to document real-world implementation of molecular classification. Sites will report use of surrogate immunohistochemistry markers (p53, MLH1, MSH2, MSH6, PMS2) and POLE testing where available to assign tumors to POLEmut, MMRd/MSI‑H, p53mut, or NSMP groups. The dataset will link molecular subgrouping with staging, adjuvant treatment choices, and early outcome measures to describe practice patterns. The goal is to characterize how molecular data are being used in routine care and where gaps or inconsistencies remain.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. be Italian healthcare hospitals that are involved in the treatment of endometrial carcinoma,
2. involved in the surgical management of EC.

Exclusion Criteria:

a) declining to participate.

Where it's running

• Fondazione Policlinico Universitario Agostino Gemelli, IRCCS
  Roma, Roma, Italy Recruiting

Study contacts

• Principal investigator: Camilla Nero — Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• Study coordinator: Camilla Nero CN Camilla Nero, PhD
• Email: camilla.nero@policlinicogemelli.it
• Phone: 0630157104

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personalized navigation to support rural and Black women with endometrial cancer

  This pilot tests a tailored patient-navigation program to help rural and Black patients with endometrial cancer access care and services.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07927244

• CR-002 study in adults with advanced solid tumors

  This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors

  Recruiting at 3 sites Phase 1/2 Crescent Biopharma, Inc. · Austin, Texas and 2 other locations · NCT07909031

• Methylation markers in self-samples to help detect gynecological cancers

  This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.

  Recruiting Universiteit Antwerpen · Edegem, Antwerp · NCT07902375

• One-Finger Technique to identify the left upper ureter during para-aortic lymphadenectomy

  This study tests a new surgical method to help surgeons find the left upper ureter during open para-aortic lymphadenectomy in women with gynecologic cancers.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07895212

• Liquid biopsy screening for early endometrial cancer in regional China

  A non-invasive blood test using cell-free DNA is being tested to see if it can detect early endometrial cancer and tell apart benign from malignant uterine lesions.

  Recruiting Guizhou Provincial People's Hospital · Guiyang, Guizhou · NCT07892755

• Radiotherapy for gynecologic cancer with up to 10 metastatic sites

  This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość · NCT07883798

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.